Skip to main content
. 2016 Jan 15;20(4):594–600. doi: 10.1111/jcmm.12729

Table 1.

Association of 34 selected SNPs with prostate cancer risk

Locus SNP Romanian population Reference studies
Risk allele Cases RAF cases Controls RAF controls OR (95% CI) P a value Reported RAF Reported per allele OR Mapped gene Reference
2p21 rs1465618 A 974 0.26 1019 0.23 1.15 (0.99–1.33) 0.069 0.23 1.08 (1.03–1.12) Intronic THADA Eeles 2009
2p15 rs721048 A 956 0.16 1014 0.14 1.13 (0.95–1.36) 0.164 0.19 1.15 (1.10–1.21) Intronic in EHBP1 Gudmundsson 2008
2q31.1 rs12621278 A 977 0.97 1020 0.97 1.06 (0.72–1.56) 0.778 0.94 1.33 (1.25–1.43) Intronic in ITGA6 Eeles 2009
3p12.1 rs2660753 C 953 0.83 1020 0.82 1.08 (0.91–1.27) 0.401 0.11 1.18 (1.06–1.31) Intergenic Eeles 2008
3q21.3 rs10934853 A 968 0.30 1020 0.29 1.04 (0.91–1.20) 0.554 0.28 1.12 (1.08–1.16) Intergenic EEFSEC Gudmundsson 2009
4q22.3 rs12500426 C 963 0.49 1021 0.47 1.08 (0.95–1.22) 0.240 0.46 1.08 1.05–1.12) Intronic in PDLIM5 Eeles 2009
4q22.3 rs17021918 C 967 0.66 1013 0.65 1.02 (0.89–1.16) 0.789 0.65 1.11 (1.08–1.15) Intronic in PDLIM5 Eeles 2009
4q24 rs7679673 C 969 0.56 1012 0.52 1.20 (1.06–1.37) 0.0037 0.55 1.1 (1.06–1.14) TET2 Eeles 2009
5p15.33 rs2736098 G 943 0.72 1006 0.69 1.15 (1.00–1.33) 0.045 0.26 1.13 (1.06–1.21) TERT Rafnar 2009
5p15.33 rs401681 T 973 0.41 1016 0.40 1.08 (0.95–1.23) 0.258 0.55 1.07 (1.03–1.11) CLPTM1L Rafnar 2009
6q25.3 rs9364554 T 946 0.27 999 0.21 1.35 (1.16–1.57) 0.000076 0.29 1.17 (1.08–1.26) Intronic in SLC22A3 Eeles 2008
7p15.2 rs10486567 G 962 0.81 1015 0.77 1.32 (1.12–1.54) 0.00046 0.77 1.12 (1.02–1.25) Intronic in JAZF1 Thomas 2008
7q21.3 rs6465657 C 957 0.43 1019 0.42 1.03 (0.91–1.17) 0.652 0.46 1.12 (1.05–1.20) Intronic in LMTK2 Eeles 2008
8p21.2 rs1512268 A 969 0.48 1014 0.45 1.13 (1.00–1.28) 0.056 0.45 1.18 (1.14–1.22) NKX3.1 Eeles 2009
8q24.21 rs16901979 A 955 0.04 1007 0.03 1.58 (1.11–2.27) 0.0098 0.03 1.79 (1.36–2.34) Intergenic POU5F1B Gudmundsson 2007
8q24.21 rs16902094 G 949 0.17 1007 0.14 1.28 (1.07–1.52) 0.0056 0.15 1.21 (1.15–1.26) Intergenic POU5F1B Gudmundsson 2009
8q24.21 rs445114 T 950 0.66 1006 0.59 1.33 (1.18–1.52) 0.000013 0.64 1.14 (1.10–1.19) Intergenic POU5F1B Gudmundsson 2009
8q24.21 rs6983267 G 955 0.54 1014 0.51 1.15 (1.01–1.30) 0.032 0.50 1.26 (1.13–1.41) Intergenic POU5F1B Yeager 2007
8q24.21 rs1447295 A 968 0.12 1009 0.09 1.27 (1.03–1.57) 0.025 0.09 1.62 (1.43–1.77) Intergenic CASC8 Gudmundsson 2007
10q11.23 rs10933994 T 964 0.45 996 0.39 1.28 (1.13–1.46) 0.00015 0.40 1.25 (1.17–1.34) Promoter of MSMB Eeles 2008. Thomas 2008
10q26.13 rs4962416 C 955 0.32 996 0.28 1.19 (1.03–1.36) 0.016 0.27 1.17 (1.05–1.30) Intronic in CTBP2 Thomas 2008
11p15.5 rs7127900 A 968 0.22 1019 0.18 1.30 (1.11–1.52) 0.0011 0.20 1.22 (1.17–1.27) TH ‐ ASCL2 Eeles 2009
11q13.2 rs12418451 A 939 0.35 976 0.30 1.22 (1.06–1.40) 0.0047 0.28 NR Zheng 2009
11q13.3 rs11228565 A 961 0.23 1004 0.20 1.18 (1.02–1.38) 0.030 0.20 1.23 (1.16–1.31) Intergenic MIR3164 ‐ MYEOV Gudmundsson 2010
11q13.3 rs10896450 G 969 0.54 1011 0.47 1.30 (1.14–1.47) 0.000047 0.46 1.13 (1.06–1.21) Gudmundsson 2009
17p12 rs4054823 T 964 0.54 1016 0.52 1.09 (0.95–1.23) 0.226 0.54b 1.13 (1.08–1.19)b Xu 2010
17q12 rs11649743 G 969 0.84 1014 0.81 1.16 (0.89–1.37) 0.080 0.80 1.28 (1.07–1.52) Intronic in HNF1B Sun 2008
17q12 rs4430796 A 972 0.57 1017 0.52 1.22 (1.08–1.39) 0.0022 0.49 1.22 (1.15–1.30) Intronic in HNF1B Gudmundsson 2007
17q24.3 rs1859962 G 972 0.52 1017 0.50 1.08 (0.95–1.22) 0.253 0.46 1.20 (1.14–1.27) Intergenic CASC17 Gudmundsson 2007
19q13.2 rs8102476 C 952 0.61 993 0.60 1.06 (0.93–1.20) 0.393 0.54 1.12 (1.08–1.15) Intergenic Gudmundsson 2009
19q13.33 rs2735839 G 965 0.88 1003 0.85 1.23 (1.02–1.49) 0.026 0.85 1.2 (1.10–1.33) KLK3 ⁄ KLK3 Eeles 2008
22q13.1 rs9623117 C 879 0.23 987 0.23 1.00 (0.85–1.17) 1.0 0.21 1.18 (1.11–1.26) Intronic TNRC6B Sun 2008
22q13.2 rs5759167 G 918 0.57 933 0.53 1.16 (1.02–1.33) 0.019 NR 1.16 (1.14–1.20) Eeles 2009
Xp11.22 rs5945572 A 916 0.41 1020 0.36 1.24 (1.03–1.49) 0.024 0.35 1.23 (1.16–1.30) NUDT11 Gudmundsson 2008
a

P‐value uncorrected for multiple testing.

b

In aggressive versus non‐aggressive cases.

RAF: Risk allele frequency.